

We thank Monneret and Bonnefont-Rousselot for their commentary. Our controlled trial design overcomes most of their concerns of course; any failure of assay techniques would not have produced a biased result, but in fact would have decreased the chances of finding any between-group effects. In our study we observed a statistically significant decrease in urinary F2-isoprostanes following the withdrawal of CPAP treatment in patients with obstructive sleep apnoea (CPAP), in a randomised, two-week trial, where those involved in the assays were entirely blind to group allocation [1]. In addition to this unexpected result, we observed no significant change in any plasma marker of oxidative stress we measured in this population (MDA, lipid hydroperoxides,) or even the production of superoxide radicals by peripheral blood mononuclear cells. It is important to note that these were morning measurements.

Regarding the methods of F2-isoprostane analysis, we used ELISA to measure F2-isoprostane because Immuno-assays are a widely used alternative for isoprostane analysis. The assay we chose for this measurement (Oxford Biomedical) is validated against GC-MS, and shows high correlation between the two methods [2]. Further, measurement by GC-MS is not required, particularly in the setting of interventional controlled clinical trials where paired samples are analysed.

Regarding the correction of F2-isoprostanes for urinary creatinine excretion, this is important in measurements of 24h (or overnight) urine collections to account for dehydration of the participants, and it is less relevant in spot urine measurement of F2-isoprostanes, where measurement of creatinine could on its own introduce further variability. To date, relatively few studies have evaluated biomarker performance by both absolute and normalized concentration, and there is no consensus on how data should be reported [3]. It has also been shown that normalizing to creatinine may briefly amplify the biomarker signal soon after a reduction in GFR [4]. Non-urinary creatinine-corrected F2-isoprostane levels are also reported in the literature, as highlighted by another randomised clinical trial which also measured F2 isoprostane in serial urine samples [5].

Regarding the estimation of SOD, this can be derived from the measurement of its enzymatic activity (which is a highly variable assay and it is preferred when assessing acute interventions) or from the measurement of its total concentration (when testing the effects of non-acute interventions that modulate gene expression, such as in our study). In any case, SOD protein levels in plasma may be more reflective of the protein levels in tissues of interest, rather than its enzymatic activity in the plasma.

The hypoxic/hyperoxic preconditioning mechanism we propose is only advanced as a hypothesis, as this study was not designed to specifically answer this question. As detailed in the paper, this was an exploratory analysis and thus it should be investigated further with properly designed mechanistic studies where this is the primary outcome. Although there was a simultaneous increase of plasma concentration of SOD and fall in urinary F2-isoprostanes in this trial, we cannot claim causality between the two. These are relatively

crude biomarkers and do not reflect the oxidation state at the level of specific tissue types (e.g. the lungs or the heart).

To conclude, despite the general belief that OSA increases oxidative stress and CPAP reduces it, the randomised and controlled clinical trials assessing this concept in patients with OSA are limited, either uncontrolled or with smaller numbers of subjects, and the results variable; the 'unexpected' results of our randomised and controlled interventional two week study are clear, and the actual assay results not in our view 'questionable'. The most important limitation we fully acknowledge in this (and all other clinical trials using systemic oxidative stress as a readout), is the absence of any reliable circulating or urinary biomarkers of oxidative stress that describe accurately tissue oxidation [6,7]. In the OSA model for example, oxidation in the lung tissue may be completely different to systemic oxidation in the cardiovascular system or the kidneys, and this may also explain the discrepancy between the various studies. Finally, as we fully acknowledged in the paper, this was a two-week study and the situation may well be different in the longer term.

Charalambos Antoniades<sup>1</sup>

Regent Lee<sup>1</sup>

Malcolm Kohler<sup>2</sup>

John Stradling<sup>3</sup>

<sup>1</sup>Division of Cardiovascular Medicine, Radcliffe Department of Medicine, John Radcliffe Campus, University of Oxford, OX3 9DU, UK

<sup>2</sup>Sleep Disorders Centre and Pulmonary Division, University Hospital of Zurich, Switzerland

<sup>3</sup>Oxford Centre for Respiratory Medicine and NIHR Oxford Biomedical Research Centre, Churchill Hospital Campus, Oxford University, OX3 7LJ, UK

## References

1. Stradling JR, Schwarz EI, Schlatzer C, Manuel AR, Lee R, Antoniades C, Kohler M. Biomarkers of oxidative stress following continuous positive airway pressure withdrawal: data from two randomised trials. *Eur Respir J* 2015; 46(4): 1065-1071.
2. Callewaert DM, Sloan C. Enzyme immunoassay of isoprostanes. *Methods Mol Biol* 2010; 610: 435-449.
3. Ralib AM, Pickering JW, Shaw GM, Devarajan P, Edelstein CL, Bonventre JV, Endre ZH. Test Characteristics of Urinary Biomarkers Depend on Quantitation Method in Acute Kidney Injury. 2012.
4. Waikar SS, Sabbiseti VS, Bonventre JV. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. *Kidney Int* 2010; 78(5): 486-494.
5. Billings FTt, Petrcek MR, Roberts LJ, 2nd, Pretorius M. Perioperative intravenous acetaminophen attenuates lipid peroxidation in adults undergoing cardiopulmonary bypass: a randomized clinical trial. *PLoS One* 2015; 10(2): e0117625.
6. Isoprostanes: Biomarkers for Oxidative Stress | Oxford Biomedical Research. 2015 [cited; Available from: <http://www.oxfordbiomed.com/node/2582>

7. Lee R, Margaritis M, Channon KM, Antoniades C. Evaluating oxidative stress in human cardiovascular disease: methodological aspects and considerations. *Curr Med Chem* 2012; 19(16): 2504-2520.